無料プレビュー

Intra-Cellular Therapies, Inc. (ITCI) · NASDAQ Global Select

プロフィール

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also

主要指標

株価: $131.87 (0.00%)
時価総額: 140億ドル
PER（今期予想）: 165.6
PBR: 11.8
配当利回り: —
52週レンジ: $64.09 – $131.98
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ Global Select
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、BDX Becton, Dickinson and Company、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、ABMD Abiomed, Inc.、RVTY Revvity, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

更新: 2026-10-09